ABNOM
☆ AI Dermatology — Free Service
Emiphumeleni ka-2022 ye-Stiftung Warentest evela eJalimane, ukwaneliseka kwabathengi nge-ModelDerm bekungaphansi kancane kunokuxhumana okukhokhelwayo kwe-telemedicine.
Emiphumeleni ka-2022 ye-Stiftung Warentest evela eJalimane, ukwaneliseka kwabathengi nge-ModelDerm bekungaphansi kancane kunokuxhumana okukhokhelwayo kwe-telemedicine.
relevance score : -100.0%
ReferencesI-laser ye‑Q‑switched Nd:YAG yaziwa ngokuphatha ngempumelelo i‑nevus ye‑Ota nezimo ezifanayo. Senze ucwaningo ukuze sibone ukuthi i‑laser ye‑high‑fluence 1064 nm Q‑switched Nd:YAG isebenza kahle kangakanani ezindaweni ezingajwayelekile zaseMongolia, ngaphandle kokulimaza isikhumba. Sahlola iziguli ezingu‑61 ezinezinhlamvu, sahlola izilonda ezingu‑70 sezizonke. Ingxenye yezilonda ilashwe nge‑laser, kanti ezinye zashiywa zingalashwa ukuze ziqhathaniswe. Sihlole imiphumela sisebenzisa isikali nedivayisi ebizwa ngokuthi i‑Mexameter® ukuze silinganise amazinga e‑melanin. Iziguli zalandelwa isikhashana sezinyanga ezingu‑14 eqenjini lokwelapha kanye nezinyanga ezingu‑18 eqenjini lokubuka. Ekupheleni kocwaningo, sithole umehluko omkhulu ezingeni lesikali nasemazingeni e‑melanin phakathi kwamaqembu alashwe nge‑laser nalawo angelashwanga, neqembu elithole imiphumela engcono. I‑laser ye‑high‑fluence Q‑switched Nd:YAG, ngaphandle kokubanga ukukhanya kwesikhumba, ibonakale isebenza kahle futhi iphephile ekwelapheni lezi zindawo ezingajwayelekile zaseMongolia.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Sifunde ukusebenza kahle nokuphepha kokusebenzisa umuthi othile we‑laser we‑ABNOM, futhi sabheka ukuthi yiziphi izici ezingathinta indlela esebenza kahle ngayo. Sibheke iziguli eziyi‑110 ezazisebenzisa i‑ABNOM futhi ezithole ukwelashwa nge‑laser okubili nesishiyagalolunye. Sithole ukuthi ukwelashwa kusebenza kangcono uma kwenziwa isikhathi eside, kodwa hhayi ezigulini esezikhulile. Iphinde yasebenza kangcono ezigulini ezinesikhumba esikhanyayo (uhlobo III) nezindawo ezincane ezithintekile (ngaphansi kuka‑10 cm²). Ukuba ne‑melasma kanye ne‑ABNOM kwenze ukwelashwa kungasebenzi kahle. Umbala noma inombolo yezindawo ezithintekile azange zenze umehluko. Cishe u‑10 % weziguli uthole amabala amnyama ngemva kokwelashwa. Ukwelashwa okuningi kwasekuqaleni kwanikeza imiphumela emihle. Iziguli ezindala ezinesikhumba esimnyama namachashaza amnyama zibe namathuba amaningi okuthola amachashaza amnyama ngemva kokwelashwa. Ezigulini ezine‑ABNOM kanye ne‑melasma, kungcono ukusebenzisa i‑laser enamandla aphansi ukugwema ukuthi i‑melasma ibe yimbi kakhulu.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Ukwelashwa
Abenzi bokwelapha abamhlophe ajwayele ukusetshenziswa. Ngokungafani ne‑melasma, i‑ABNOM ingathuthukiswa ngokwelashwa nge‑laser futhi ingasuswa ngaphandle kokuphinda. Ukwelashwa nge‑Laser kungenziwa izikhathi ezingu‑10 kuya kwezingu‑20 ukwelapha i‑ABNOM.
#QS1064 laser